Group 1 - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is considered one of the best low-cost stocks to buy according to analysts, with a maintained Buy rating and a price target of $640 by Evan Seigerman from BMO Capital [1] - The strong results from Phase 3 trials for the company's cat and birch allergy antibody cocktails demonstrated significant symptom reduction, particularly in ocular itch, redness, and skin reactions for cat allergy patients sensitized to FelD1 [2] - The clinical data from the trials address a large unmet medical need, although there is uncertainty regarding commercial uptake due to the dominance of generic antihistamines in allergy treatment [3] Group 2 - Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on developing, manufacturing, and selling medicines for serious diseases [3]